As per our research report, the size of the global superdisintegrants market is projected to reach USD 386.3 Million in 2023. This value is estimated to grow at a CAGR of 7.8% from 2024 to 2029 and be worth USD 606.2 Million by 2029 from USD 416.4 Million in 2024.
Superdisintegrants are one of the many excipients utilized in the pharmaceutical industry for tablet-based drug administration. Disintegrants are substances that expand and dissolve when wet causing the tablet to break apart in the digestive tract, releasing active ingredients for absorption. In addition, they make sure that when the tablet is in contact with water, it breaks down rapidly into smaller fragments, making way for dissolution, thus reducing the time required for the drug release.
Worldwide healthcare expenditure is growing continuously, and the trend is anticipated to grow in the coming years. The rising aging population, growing chronic disease patient count, and increasing costs of medical technologies are contributing to the growing healthcare expenditure worldwide. According to statistics published by the World Health Organization (WHO), worldwide healthcare expenditure was valued at USD 6.5 Trillion in 2010 and increased to USD 9.7 Trillion in 2019. The developed countries accounted for the major proportion of global healthcare spending. On the other hand, healthcare spending from developing and underdeveloped countries is also increasing as they seek better healthcare access and increasing the burden of various diseases. The growing healthcare expenditure results in the growing consumption of superdisintegrants and boosts the market’s growth rate.
The growth of the global superdisintegrants market is further attributed to factors such as the growing population of geriatric and pediatric patients, the growing generic drugs market, and the development of new superdisintegrants in the pharmaceutical industry. In addition, increasing demand for manufacturing highly accurate and useful drugs with appropriate dosage levels of various excipients and active ingredients elevates the market's growth rate. Furthermore, the growing healthcare expenditure and increasing disposable income in urban areas are further propelling the superdisintegrants market growth.
The main goal of drug manufacturers is to reduce the dissolving time of a tablet in the digestive part and release active ingredients, which is solely to set up growth opportunities for the market. The growing prevalence of producing generic drugs is also fuelling the market's growth. In addition, rising incidences of chronic diseases and other health disorders due to lifestyle changes and food habits create chances for the market to grow eventually.
Although synthetic Superdisintegrants have been the standard for many decades, more significant research into natural Superdisintegrants will motivate the future growth of the global superdisintegrants market.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Analysed |
By Product Type, Application, Therapeutic Area & Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
Key Market Players |
Ashland, BASF SE, FMC Corporation, JRS Pharma, DFE Pharma, Roquette, The Dow Chemical Company, Asahi Kasei Corporation, Nippon Soda Co, Huber Corporation. |
The natural superdisintegrants segment is predicted to have the highest CAGR during the forecast period owing to the increasing prevalence of organic raw materials to manufacture various drugs that configure lower side effects.
However, the synthetic superdisintegrants segment had the largest share of the global market in 2022 and is expected to showcase healthy occupancy in the market in the coming years. Furthermore, under the sub-segments, the crospovidone segment is anticipated to showcase a healthy CAGR during the forecast period.
The capsules segment is projected to witness a major share of the global superdisintegrants market in 2023, and the domination of the segment is likely to continue during the forecast period due to the increasing production rate of the drugs to meet the end-users requirements.
The gastrointestinal diseases segment is expected to lead the market during the forecast period. The growing popularity of over-the-counter drugs and the rise in the support from private and public organizations through investments mainly to improve the quality of treatment procedures is leveraging the segment's growth rate. Superdisintegrants are used to treat various gastrointestinal diseases such as gastrointestinal diseases, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and gastroesophageal reflux disease (GERD). Croscarmellose sodium, crospovidone, sodium starch glycolate, and pregelatinized starch are some of the most common superdisintegrants used to treat GI diseases.
North America led the market in 2023 and the domination of the North American region is anticipated to continue throughout the forecast period. Increasing financial support for developing innovative oral dosage forms and constant effort devoted to providing superior quality and compliant products in the market are the primary factors responsible for the dominance of North America. In addition, the growing adoption of oral dosage forms such as tablets and capsules and the increasing demand for technological advancements such as drug delivery is forecasted to result in regional market growth. Countries such as the United States and Canada contribute significantly to the North American market growth.
Europe held a substantial global market share in 2023. The EU market is expected to register a healthy CAGR during the forecast period. The growing investments and increasing R&D efforts from the market participants are predicted to result in the growth of the European market. Countries such as UK and Germany are expected to account for a major share of the European market in the coming years.
The Asia-Pacific is expected to grow the fastest due to increasing healthcare spending, rising healthcare infrastructure and awareness, and growing outsourcing of excipient manufacturing to Asian countries like India and China. The synthetic superdisintegrants market segment held the largest share of the global superdisintegrants market. It mainly accounts for the prevalent use of excipients such as sodium starch glycolate and crospovidone in oral and fast-disintegrating tablets. Rising incidences of cardiovascular diseases, neurological diseases, and other related diseases are expected to drive the demand for fast-disintegrating tablets, driving the market of Superdisintegrants during the forecast period.
Companies playing a promising role in the global superdisintegrants market and profiled in this report are Ashland, BASF SE, FMC Corporation, JRS Pharma, DFE Pharma, Roquette, The Dow Chemical Company, Asahi Kasei Corporation, Nippon Soda Co, Huber Corporation.
By Product Type
By Application
By Therapeutic Area
By Region
Frequently Asked Questions
The global superdisintegrants market size was worth USD 358.4 million in 2022.
The global superdisintegrants market is anticipated to grow at a CAGR of 7.8% from 2023 to 2028.
The Asia-Pacific region is anticipated to register fastest CAGR in the global market in the coming years.
Ashland, BASF SE, FMC Corporation, JRS Pharma, DFE Pharma, Roquette, The Dow Chemical Company, Asahi Kasei Corporation, Nippon Soda Co, Huber Corporation are some of the notable players in the superdisintegrants market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region